Blueprint Medicines (BPMC) Tops Q1 EPS by 50c ; Offers Guidance

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of $0.01, $0.50 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $149.41 million versus the consensus estimate of $156.83 million.

GUIDANCE:

Blueprint Medicines sees FY2025 revenue of $700-720 million, versus the consensus of $723.2 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• SCWorx gets Nasdaq panel approval to maintain listing with conditions
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance